![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-adgif-27965.gif)
![AbbVie](https://www.pharmacompass.com/image/flap/abbvie-corp-ad-w33-mob-headergif-39012.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will leverage Huadong Medicine's advanced innovative drug discovery and screening characterization platform, in combination with Insilico's end-to-end AI-driven drug discovery platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Insilico Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2021
Details:
Partnership accelerates development path for Mirvetuximab in Greater China and expands Huadong Medicine’s oncology portfolio with innovative ADC.
Lead Product(s): Mirvetuximab Soravtansine
Therapeutic Area: Oncology Product Name: IMGN853
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Immunogen
Deal Size: $305.0 million Upfront Cash: $40.0 million
Deal Type: Collaboration October 19, 2020